期刊文献+

6种肿瘤标记物联合检测在肺癌诊断中的应用 被引量:1

原文传递
导出
摘要 本文应用放射免疫法和酶联免疫法检测128例肺癌病人、42例肺良性病变病人及43例正常健康人的血清中CEA、NSE、CYFRA21-1、TPA、CA15-3、CA242的水平,以探讨联合检测在肺癌诊断中的应用价值。结果表明肺癌组血清6种指标均高于肺良性病变组及正常组;如以一项阳性作为肺癌的诊断依据,则Sq、AC、SCLC的阳性率可分别达97.5%、100%、95.8%,认为6种指标对不同组织类型肺癌有诊断价值,其联合检测可以提高肺癌诊断的敏感性,对鉴别病理类型亦有意义。
出处 《中国医师杂志》 CAS 2005年第9期1261-1262,共2页 Journal of Chinese Physician
  • 相关文献

参考文献12

二级参考文献24

  • 1刘忠,郭述良.检测支气管肺泡灌洗液肿瘤标记物CA242在早期诊断周围型肺癌的价值[J].中国肿瘤临床,1996,23(10):739-739. 被引量:3
  • 2夏吉荣,黄天禄,马志如,刘忠.血清CA_(242)测定的临床应用评价[J].中国肿瘤临床,1997,24(1):40-42. 被引量:33
  • 3[1]Foa P, Fornier M, Miceli R et al. Tunout markers CEA, NSE, SCC,TPA and CYFRA21 1in resectable non small cell lung cancer. Anticancer Res,1999,19(4c) :3613
  • 4[4]Brechot JM, Chevret S, Nataf J etal. Diagnostic and prognostic value of CYFRA21-1 compared with other tumor markers in patients with NSCLC:a prospective study of 116 patients. Eur J Cancer,1997,33(3) :385
  • 5[1]Cooper EH.Neuron-specific enolase[J].Int J Biol Markers,1994,9(4):205-210.
  • 6[2]Niklinski J,Furman M,Chyczewska E,et al.Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer[J].Eur Respir J,1995,8(2):291-294.
  • 7[3]Maeda Y,Segawa Y,Takigawa N,et al.Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer[J].Intern Med,1996,35(10):764-771.
  • 8[4]Mitsuhashi N,Takahashi T,Sakurai H,et al.Establishment and characterization of a new human lung poorly differentiated adenocarcinoma cell line,GLL-1,producing carcinoembryonic antigen (CEA) and CA19-9[J].Lung Cancer,1995,12(1-2):13-24.
  • 9[5]Diez M,Gomez A,Hernando F,et al.Serum CEA,CA125,and SCC antigens and tumor recurrence in resectable non-small cell lung cancer[J].Int J Biol Markers,1995,10(1):5-10.
  • 10[6]Pujol JL,Grenier J,Parrat E,et al.Cytokeratins as serum markers in lung cancer:a comparison of CYFRA 21-1 and TPS[J].Am J Respir Crit Care Med, 1996,154(3 Pt 1):725-733.

共引文献117

同被引文献40

  • 1张昕,张湘茹.肺癌肿瘤标志物的临床价值[J].癌症进展,2005,3(2):159-162. 被引量:42
  • 2宋丽华,宋现让,张锡芹,齐洁琳,李秀菊,田禾,步兵.小细胞肺癌患者预后因素分析[J].中华肿瘤杂志,2004,26(7):413-416. 被引量:23
  • 3李长生,程邦昌,戈伟,高建飞.血清和胸水中肿瘤标志物检测对老年人胸腔积液的诊断价值[J].中华老年医学杂志,2004,23(10):697-700. 被引量:17
  • 4Salgia R, Harpole D, Hamdon JE, et al. Role of serum tumor markers CA125 and CEA in non-small cell lung cancer[J]. Anticancer Res,2001,21 (2B) :1241 - 1246.
  • 5Ebert W, Muley T,Trainer C, et al. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC[ J].Anticance Res,2002,22(2B) : 1083 - 1089.
  • 6Satoh H ,Ishikawa H ,Kurishima K,et al. Cut-off levels of NSE to differentiate SCLC from NSCLC[J]. Oncol Rep,2002,9(3) :581 -583.
  • 7Ando S, Kimura H, lwai N, et al. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer [ J ]. Anticaneer Res, 2001,21 (4B) :3085 -3092.
  • 8Lai RS,Chen CC,Lee PC,et al. Evaluation of cytokeratin 19 fragment ( CYFRA21-1 ) as a tumor marker in malignant pleural effusion [ J ]. Jpn J Clin Oncol, 1999,29 ( 9 ) :421 - 424.
  • 9Chen G, Gharib TG, Huang CC, et al. Proteomic analysis of lung adenocarcinoma : identification of a highly expressed set of proteins in tumors[ J]. Clin Cancer Res ,2002,8 ( 17 ) :2298 - 2305.
  • 10Shitrit D,Zingerman B,Shitrit AB,et al. Diagnostic value of CYFRA 21-1,CEA, CA19-9, CA15-3 and CA125 assays in pleural effusions:a analysis of 116 cases and review of the literature [ J]. The Oncologist,2005,10 ( 7 ) :501 - 507.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部